

Ref. No: FOI2034  
Date: 05/09/2025  
Subject: Biologics Rheumatology

## REQUEST & RESPONSE

**Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:**

- Abatacept [Orencia] 17
- Adalimumab [Humira] 7
- Adalimumab Biosimilars 201
- Apremilast [Otezla] 1
- Baricitinib [Olumiant] 13
- Bimekizumab [Bimzelx] 4
- Certolizumab [Cimzia] 15
- Etanercept [Enbrel] 5
- Etanercept Biosimilars 98
- Filgotinib [Jyseleca] 0
- Golimumab [Simponi] 12
- Guselkumab [Tremfya] 4
- Infliximab [Remicade] 0
- Infliximab Biosimilars 14
- Ixekizumab [Taltz] 4
- Risankizumab [Skyrizi] 0
- Rituximab [MabThera] 1
- Rituximab Biosimilars 19
- Sarilumab [Kevzara] 1
- Secukinumab [Cosentyx] 38
- Tocilizumab [Ro Actemra] 27
- Tocilizumab Biosimilars 0
- Tofacitinib [Xeljanz] 3
- Upadacitinib [Rinvoq] 4
- Ustekinumab [Stelara] 0
- Ustekinumab Biosimilar 5

**Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis (PsA) ONLY in the last 3 months with the following drugs.**

- Abatacept [Orencia] 0
- Adalimumab [Humira] 1
- Adalimumab Biosimilars 45
- Apremilast [Otezla] 1
- Bimekizumab [Bimzelx] 3
- Certolizumab [Cimzia] 4
- Etanercept [Enbrel] 1
- Etanercept Biosimilars 24
- Golimumab [Simponi] 1
- Guselkumab [Tremfya] 4
- Infliximab [Remicade] 0
- Infliximab Biosimilars 4
- Ixekizumab [Taltz] 3
- Risankizumab [Skyrizi] 0
- Secukinumab [Cosentyx] 22
- Tofacitinib [Xeljanz] 1
- Upadacitinib [Rinvoq] 0
- Ustekinumab [Stelara] 0
- Ustekinumab Biosimilar 5